Abstract: The invention provides siRNA compositions for inhibiting gene expression in targeted cells. A multi-targeting siR-NA-aptamer platform is provided that is efficiently delivered and is processed by cellular RNAi machinery to produce one, two or more siRNAs. Methods of using the multi-targeting siRNA-aptamer for selectively targeting cancer cells to downregulate the expression of multiple genes are also provided.

Abstract: The invention provides siRNA compositions for inhibiting gene expression in targeted cells.

Abstract: The invention provides siRNA compositions for inhibiting gene expression in targeted cells.

Abstract: A multi-targeting siRNA-aptamer platform is provided that is processed by cellular RNAi machinery to produce siR-NAs. The constructs according to the invention are targeted at cells of the immune system. Methods of using the multi-targeting siR-NA-aptamer for selectively targeting cells to down-regulate the expression of multiple genes are also provided.

Abstract: The present invention relates to the use of light-emitting, water soluble nanoparticles in the treatment of disorders of the central nervous system.

Abstract: There is provided improved therapy methods and apparatus for treating a patient's brain and spinal cord. The apparatus further relates to a flexible surgical balloon or cap-like device comprising one or more material layers that may have an antimicrobial element. The therapy apparatus may include portals for introducing diagnostic monitoring and/or therapeutic devices, and delivery of therapeutic drug delivery systems. Certain embodiments of the invention have an output emission area positioned to irradiate a portion of the brain with an efficacious power density and wavelength of light for diagnostic and/or therapeutic purposes.

Abstract: Combination of agents that increase the amount of reactive oxygen species with agents that are activated, enhanced, or induced by oxygen species for the treatment of cancer and pre-cancerous disease. Pharmaceutical compositions comprising a therapeutic agent or drug that generate or produce reactive oxygen species (ROS) in a disease microenvironment, and at least one drug or agent that is activated, enhanced, or induced by ROS for the treatment of mammalian cancer, dysplastic disorders, neoplastic, or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer dysplastic disorders, neoplastic, or hyperproliferative disorders.

Abstract: A computer system maintains a biological data structure having molecular feature data. The system receives data elements indicating biological molecular features and knowledge elements that represent biological concepts. The system individually associates unique identifiers with the elements. For individual elements, the system maintains an internal element set of the other unique identifiers for the other elements that are directly associated with that one individual element. For the individual elements, the system maintains an external element set of the other unique identifiers for the other elements that have that one individual element in their own internal element sets. Although not required, the computer system may process a query indicating a search scope and a molecular feature for an individual biological entity, and responsively process the molecular feature and the elements based on the search scope to induce a knowledge sub-graph for the individual biological entity.

Abstract: A computer system maintains a biological data structure having molecular feature data. The system receives data elements indicating biological molecular features and knowledge elements that represent biological concepts. The system individually associates unique identifiers with the elements. For individual elements, the system maintains an internal element set of the other unique identifiers for the other elements that are directly associated with that one individual element. For the individual elements, the system maintains an external element set of the other unique identifiers for the other elements that have that one individual element in their own internal element sets. Although not required, the computer system may process a query indicating a search scope and a molecular feature for an individual biological entity, and responsively process the molecular feature and the elements based on the search scope to induce a knowledge sub-graph for the individual biological entity.

Abstract: A computer system maintains a biological data structure having molecular feature data. The system receives data elements indicating biological molecular features and knowledge elements that represent biological concepts. The system individually associates unique identifiers with the elements. For individual elements, the system maintains an internal element set of the other unique identifiers for the other elements that are directly associated with that one individual element. For the individual elements, the system maintains an external element set of the other unique identifiers for the other elements that have that one individual element in their own internal element sets. Although not required, the computer system may process a query indicating a search scope and a molecular feature for an individual biological entity, and responsively process the molecular feature and the elements based on the search scope to induce a knowledge sub-graph for the individual biological entity.

Abstract: The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.

Abstract: The invention comprises a method of identifying or predicting the predisposition to endometriosis in a female subject comprising determining the level of gene expression of at least one differentially-expressed gene or protein or peptide of peripheral blood leukocytes in a sample of peripheral blood leukocytes or peripheral blood in a subject to provide a first value, determining the level of gene expression of the at least one differentially-expressed gene or protein or peptide of said leukocytes in a control or reference standard to provide a second value, and comparing whether there is a difference between the first value and second value.

Abstract: The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.

Abstract: The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.